Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1161-1168

  Licitra, Lisa ^a   Störkel, Stephan ^b   Kerr, Keith M ^c   Van Cutsem, Eric ^d   Pirker, Robert ^e   Hirsch, Fred R ^f   Vermorken, Jan B ^g   Von Heydebreck, Anja ^h   Esser, Regina ^h   Celik, Ilhan ^h   Ciardiello, Fortunato ⁱ  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h MERCK KGAA   (Germany)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biomarker; Cetuximab; CRYSTAL; Epidermal growth factor receptor; EXTREME; First line chemotherapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; K RAS PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875734469     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.018     Document Type: Article

References (22)

1. J.B. Vermorken, R. Mesia, and F. Rivera Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 11 2008 1116 1127
2. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
3. E. Van Cutsem, C.H. Kohne, and I. Lang Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 15 2011 2011 2019
4. R. Pirker, J.R. Pereira, and A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 9674 2009 1525 1531
5. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 7 2011 1535 1546
6. K.J. O'Byrne, U. Gatzemeier, and I. Bondarenko Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study Lancet Oncol 12 8 2011 795 805
7. N. Van Damme, P. Deron, and N. Van Roy Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas BMC Cancer 10 2010 189
8. T. Hirano, P.E. Steele, and J.L. Gluckman Low incidence of point mutation at codon 12 of K-ras proto-oncogene in squamous cell carcinoma of the upper aerodigestive tract Ann Otol Rhinol Laryngol 100 7 1991 597 599
9. R. Pirker, J.R. Pereira, and J. von Pawel EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 2012 33 42
10. M. Bonetti, and R.D. Gelber A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data Stat Med 19 19 2000 2595 2609
11. R.I. Nicholson, J.M. Gee, and M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl. 4 2001 S9 S15
12. E. Pectasides, T. Rampias, and P. Kountourakis Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma Clin Cancer Res 17 9 2011 2947 2954
13. S.E. Wheeler, D.R. Siwak, and R.L. Chai Tumor epidermal growth factor receptor (EGFR) and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma Clin Cancer Res 18 2012 2278 2289
14. H.M. Coley, C.F. Shotton, A. Ajose-Adeogun, H. Modjtahedi, and H. Thomas Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents Biochem Pharmacol 72 8 2006 941 948
15. Y. Hiraishi, T. Wada, and K. Nakatani EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines Pathol Oncol Res 14 1 2008 39 43
16. W. Lei, J.E. Mayotte, and M.L. Levitt Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells. Anticancer Res 19 1A 1999 221 228
17. L. Licitra, R. Mesia, and F. Rivera Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study Ann Oncol 22 5 2011 1078 1087
18. C. Campanella, M. Mottolese, and A. Cianciulli Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab J Transl Med 8 2010 36
19. F. Cappuzzo, G. Finocchiaro, and E. Rossi EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 4 2008 717 723
20. P. Laurent-Puig, A. Cayre, and G. Manceau Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer J Clin Oncol 27 35 2009 5924 5930
21. N. Personeni, S. Fieuws, and H. Piessevaux Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study Clin Cancer Res 14 18 2008 5869 5876
22. M. Scartozzi, I. Bearzi, and A. Mandolesi Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis BMC Cancer 9 2009 303